UCM and MIT research shows transient CB2R modulation locks breast cancer cells into less aggressive state

A brief period of cannabinoid receptor 2 (CB2R) modulation produced lasting changes in breast cancer cell identity, pushing tumor cells toward a less aggressive, luminal-like state that persisted after treatment ended and resisted multiple signals promoting dedifferentiation, according to a preclinical study published August 22 in Communications Biology.

The study, led by María Salazar-Roa at the Complutense University of Madrid (UCM) and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), suggests that transient pharmacological intervention can durably constrain cancer cell plasticity — the ability of tumor cells to shift between differentiated and more stem-like or mesenchymal states associated with treatment resistance and metastasis.

Transient treatment produces lasting change

Cancer cell plasticity contributes to tumor heterogeneity by allowing malignant cells to adopt different phenotypic states in response to treatment and changes in the tumor microenvironment. In breast cancer, transitions toward stem-like and mesenchymal states have been associated with increased invasiveness, tumor initiation, and resistance to therapy.

The researchers found that brief, low-dose CB2R modulation in patient-derived and murine breast tumor organoids initially induced a transitional transcriptional state that progressively resolved into a more differentiated, luminal-like phenotype. The effect persisted after the pharmacological intervention ended.

RNA sequencing across the transition showed progressive changes in gene expression, while CUT&Tag chromatin profiling identified accompanying chromatin remodeling, suggesting that stabilization of the new cell state was reinforced at the epigenetic level rather than reflecting only a transient transcriptional response.

Cells that adopted the luminal-like state showed reduced self-renewal, invasiveness, and tumor-initiating capacity. They also resisted attempts to drive them back toward less differentiated states using multiple challenges, including TGFβ exposure, stromal co-culture, immune signaling, and mechanical stress.

The researchers further demonstrated persistence of the phenotype following orthotopic transplantation in mice, providing in vivo evidence that the effect could be maintained beyond the initial treatment period.

Tamoxifen sensitivity returns

The shift in cell identity also affected treatment response. CB2R modulation increased sensitivity to tamoxifen, consistent with tumor cells reacquiring characteristics of hormone-responsive luminal breast cancer.

That finding raises the possibility that restricting tumor plasticity could do more than reduce aggressive cellular behavior: it could potentially restore sensitivity to therapies that become less effective as cancer cells move away from differentiated lineage states.

The concept has parallels with differentiation therapy in hematologic cancers, most notably the use of all-trans retinoic acid in acute promyelocytic leukemia. Rather than primarily attempting to kill malignant cells, differentiation-based approaches seek to push them toward a more mature and less malignant state.

The breast cancer study differs in proposing that a transient receptor-mediated intervention may be sufficient to produce a durable change in tumor cell identity, potentially avoiding the need for continuous pharmacological suppression of the underlying pathway.

CB2R takes on a different role

CB2R is a G protein-coupled cannabinoid receptor studied extensively in immune and inflammatory biology. The new findings suggest an additional role in regulating cancer cell state and identify CB2R signaling as a potential entry point for manipulating breast cancer plasticity.

The approach remains distinct from established epigenetic therapies such as histone deacetylase and EZH1/2 inhibitors, which directly target enzymes controlling chromatin state. Here, CB2R modulation acts upstream through receptor signaling, with the resulting phenotypic transition accompanied by longer-lasting changes in chromatin organization.

CB2R has previously been investigated pharmacologically in inflammatory and pain indications, but selective modulation of the receptor has not become an established oncology strategy. A Phase Ia window-of-opportunity study is evaluating oral cannabidiol in patients with invasive breast cancer, but cannabidiol is a non-selective, multi-target cannabinoid and the trial is not testing the selective CB2R-mediated differentiation mechanism described in the new study.

Early-stage route toward controlling tumor plasticity

The findings remain preclinical. The researchers have not disclosed a named therapeutic candidate, clinical development program, or plans for human testing, and whether the durable cell-state changes observed in organoids and mouse models can be reproduced safely in patients remains unknown.

The work nevertheless suggests a different way of approaching one of the persistent problems in solid tumor treatment. Rather than continuously targeting individual pathways that cancer cells can potentially escape through phenotypic adaptation, transient CB2R modulation may restrict the cells' ability to change state in the first place.

Further work will be needed to establish the molecular mechanisms linking CB2R signaling to chromatin remodeling, determine which breast cancer subtypes are most susceptible to the intervention, and identify pharmacological agents suitable for clinical development.

The study was led by researchers at UCM and imas12, with collaborators from Spanish institutions including the CBM Severo Ochoa, Spanish National Cancer Research Center (CNIO), and Hospital La Paz, alongside contributors affiliated with the Harvard-MIT Biomedical Engineering Center and MIT Institute for Medical Engineering and Science.

---

Spot something wrong? Report an issue with this article